| scholarly article | Q13442814 |
| P2093 | author name string | Nurzen Sezgin | |
| Okan Bakiner | |||
| Nilgun Guvener Demirag | |||
| Melek Eda Ertorer | |||
| Neslihan Bascil Tutuncu | |||
| Inan Anaforoglu | |||
| P2860 | cites work | Pathogenesis of osteoporosis: concepts, conflicts, and prospects | Q24536164 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families | Q28137631 | ||
| The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis | Q28241336 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Strontium ranelate: a novel mode of action optimizing bone formation and resorption | Q33983525 | ||
| Severely suppressed bone turnover: a potential complication of alendronate therapy | Q33983792 | ||
| Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. | Q34319046 | ||
| Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling | Q34384039 | ||
| The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro | Q34734649 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| Is the calcium receptor a molecular target for the actions of strontium on bone? | Q35121401 | ||
| Clinical effects of strontium ranelate in women with postmenopausal osteoporosis | Q35971470 | ||
| Clinical practice. Screening for osteoporosis | Q36193168 | ||
| Strontium ranelate: a physiological approach for optimizing bone formation and resorption | Q36378506 | ||
| Simple test of intestinal calcium absorption measured by stable strontium. | Q41985186 | ||
| Rapid colorimetric determination of calcium in biologic fluids with methylthymol blue | Q42233969 | ||
| S 12911-2 inhibits osteoclastic bone resorption in vitro | Q42443380 | ||
| Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles | Q43601703 | ||
| Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial | Q43982424 | ||
| In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation | Q44100791 | ||
| Extracellular Calcium Is a Potent Inducer of Cyclo-oxygenase-2 in Murine Osteoblasts Through an ERK Signaling Pathway | Q44636334 | ||
| In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor | Q45080847 | ||
| Effects of low doses of strontium on bone quality and quantity in rats | Q68622902 | ||
| Effect of low doses of stable strontium on bone metabolism in rats | Q70063557 | ||
| High serum osteoprotegerin and low RANKL in primary biliary cirrhosis | Q73187923 | ||
| The diagnosis and management of osteoporosis | Q73685821 | ||
| Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women | Q78057526 | ||
| Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib | Q80049108 | ||
| The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? | Q80437863 | ||
| P433 | issue | 4 | |
| P921 | main subject | osteoporosis | Q165328 |
| postmenopausal osteoporosis | Q55950294 | ||
| P304 | page(s) | 217-225 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Current Therapeutic Research | Q15752574 |
| P1476 | title | Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study | |
| P478 | volume | 68 |
Search more.